Please note: AABB reserves the right to make updates to this program.
Thursday, June 20, 2019
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 19EL-447 (see program format numbers below under Registration)
Educational Track: Quality Education
Topic: Transfusion Medicine (Hemovigilance)
Intended Audience: CEOs, Directors, Donor Recruitment Staff, Hospitals, Hospital Blood Banks, Managers/Supervisors, Medical Directors, Nurses, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Transfusion Safety Officers
Teaching Level: Basic
Director: Srijana Rajbhandary, BDS, MPH, Research and Data Analyst, AABB, Bethesda, MD
Moderator: Jo Wiersum, MD, National Medical Coordinator, Transfusion and Transplantation Reactions in Patients (TRIP), Netherlands
Speakers: Arlinke Bokhorst, MD, Transfusion and Transplantation Reactions in Patients (TRIP), Netherlands; Dr. Shruthi Narayan, Medical Director, Serious Hazards of Transfusion (SHOT), United Kingdom; Dr. Imad Sandid, Haemovigilance Officer, French National Agency for Medicines and Health Product Safety (ANSM), France; Jo Wiersum, MD, National Medical Coordinator, Transfusion and Transplantation Reactions in Patients (TRIP), Netherlands
After participating in this educational activity, participants should be able to:
- Describe strengths of the UK, Netherlands and French hemovigilance systems.
- Describe the flow of communication and interaction among the various systems.
- Discuss how other hemovigilance systems can benefit from lessons learned from these systems.
- Discuss the current work of these systems.
This program will help hemovigilance enthusiasts around the world understand the background, organizational structure, lessons learned and current exciting work from established hemovigilance systems: the SHOT (UK), TRIP (Netherlands) and ANSM (French National Agency for the Safety of Medicines and Health Products). The program will highlight the global shift towards increased biovigilance activities and also describe the flow of communication and interaction among the various systems.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||
Continuing Education Credit
AABB estimates both the live and on-demand version of this eCast each to be eligible for 1.5 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. For more information on each credit type please visit our
Continuing Education Credits webpage.
Dr. Imad Sandid, PharmD, PhD in Medical Biology, started his career in 1988 as a hospital laboratory practitioner in medical biology. Since 1992, he has been working in the field of blood transfusion and built up a broad range of expertise, both nationally and internationally. At French National Agency for the Safety of Medicines and Health Products (ANSM), he holds several positions, including team manager for the regulation and traceability of blood components; and national manager of database coding for Blood Establishment codes, blood component codes and biological analysis codes. He also serves as the project manager for the e-FIT, secure electronic haemovigilance reporting system, and coordination of national vigilances (haemovigilance, medical devices vigilance and in vitro device vigilance); and national haemovigilance officer (since 2008). In addition, Sandid is a board member on the French Advisory Group (FAG), where he is responsible for the surveillance of emerging agents that are potentially transmissible by Substances of Human Origin (SoHO). He serves as the national coordinator for annual reports and surveys (European Commission, Council of Europe, WHO and International Haemovigilance Network), as well. Sandid has been instrumental in establishing strategic plans and procedures for blood Establishment inspections; external quality control of blood components (laboratory of the competent authority for blood); and protocols for evaluating blood components for quality, safety and efficacy. Additionally, Sandid holds pivotal roles in strengthening European and other international haemovigilance initiatives as an expert in the field, as well as a representative of the French haemovigilance system. He contributes his expertise to the group of the Competent Authorities on Substances of Human Origin Expert Group (CASoHO) since 2000, as well as several European working groups ─ the vigilance working sub-group, the working group on the exchange of surplus blood between European countries, the working group on a rapid alert platform for haemovigilance in Europe and the working group on the surveillance of emerging transfusion-transmissible agents that can be transmitted by SoHO (preparedness plans for WNV, Zika etc.).
Dr. Jo Wiersum obtained her medical degree in Leiden in 1981 and went on to work in the UK and the Republic of Guinea (West Africa). Since 1996 she has worked as a donor physician for the Dutch blood supply organisation, Sanquin. In 2000 she completed specialty training in community medicine. Since 2002 when the Dutch national hemovigilance office TRIP started, she has been its national medical coordinator. TRIP stands for Transfusion and Transplantation Reactions in Patients because it also handles reports on tissue and cell vigilance. Jo has chaired of the International Society for Blood Transfusion haemovigilance working party since 2011. In 2013 she obtained a PhD in medicine on a thesis entitled Hemovigilance: is it making a difference to safety in the transfusion chain.